BioLineRx Ltd (BioLineRx) is a biopharmaceutical company focused on developing therapies in oncology and rare diseases. The company's lead product, APHEXDA (motixafortide), is a novel peptide designed for stem cell mobilization and the treatment of solid tumors. It has received FDA approval for use in combination with G-CSF to facilitate the mobilization of hematopoietic stem cells from patients with multiple myeloma for autologous transplantation. APHEXDA is being developed and commercialized by Ayrmid Pharma Ltd globally, excluding Asia, and by Gloria in Asia.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

BioLineRx is actively engaged in research and development initiatives focused on oncology and rare diseases. The company's R&D efforts are primarily directed towards advancing its pipeline of therapeutic candidates, with a significant emphasis on motixafortide and GLIX1. Motixafortide has received FDA approval for stem cell mobilization in multiple myeloma patients, and the company is conducting a long-term follow-up of GENESIS patients. Additionally, an investigator-initiated Phase 2b trial for pancreatic ductal adenocarcinoma is ongoing, sponsored by Columbia University and supported equally by BioLineRx and Regeneron. A Phase 1 study for gene therapies in sickle cell disease was initiated in collaboration with Washington University School of Medicine. In September 2025, BioLineRx entered into a collaboration with Hemispherian for the development and commercialization of GLIX1, targeting DNA damage response in glioblastoma and other cancers. BioLineRx is committed to identifying and advancing therapeutic candidates that offer clear differentiation from existing treatments, focusing on superior efficacy, improved safety, and novel mechanisms of action. The company employs a systematic approach to asset identification, rigorous scientific and clinical validation, and disciplined in-licensing. BioLineRx aims to continue its R&D efforts by pursuing new partnerships and in-licensing opportunities to expand its product pipeline, focusing on developing innovative assets with significant potential value.